General Information of Drug (ID: DM0DIEZ)

Drug Name
UNI-rhIL-11 Drug Info
Synonyms Recombinant human interleukin 11 (thrombocytopenia), Uni-Bio Science Group; RhIL-11 (thrombocytopenia), Uni-Bio Science Group
Indication
Disease Entry ICD 11 Status REF
Thrombocytopenia 3B64 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM0DIEZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Oprelvekin DMTSRI6 Inflammatory bowel disease DD72 Approved [3]
BMTP-11 DMB6FMH Prostate cancer 2C82.0 Phase 1 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 11 receptor alpha (IL11RA) TTZPLJS I11RA_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01663441) A Phase Study of Genetically Modified Recombinant Human Interleukin-11. U.S. National Institutes of Health.
2 Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5.
3 Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71.
4 Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 1;21(13):3041-51.